相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
Nicholas F. Kuhn et al.
CANCER CELL (2019)
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Darya Alizadeh et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Mikhail Binnewies et al.
CELL (2019)
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
Linda Hammerich et al.
NATURE MEDICINE (2019)
Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression
Sherly Mardiana et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Cryptic activation of an Irf8 enhancer governs cDC1 fate specification
Vivek Durai et al.
NATURE IMMUNOLOGY (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Antagonism of IAPs Enhances CAR T-cell Efficacy
Jessica Michie et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Switching on the green light for chimeric antigen receptor T-cell therapy
Sherly Mardiana et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
Alvaro de Mingo Pulido et al.
CANCER CELL (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2018)
Altered compensatory cytokine signaling underlies the discrepancy between Flt3-/- and Flt3l-/- mice
Vivek Durai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
Mauro P. Avanzi et al.
CELL REPORTS (2018)
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2018)
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells-Response
Fernando P. Canale et al.
CANCER RESEARCH (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman et al.
CELL (2018)
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Paul A. Beavis et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
Markus Chmielewski et al.
CELL REPORTS (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells
Sherly Mardiana et al.
CANCER RESEARCH (2017)
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Alfonso R. Sanchez-Paulete et al.
CANCER DISCOVERY (2016)
Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
Edward W. Roberts et al.
CANCER CELL (2016)
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells (vol 30, pg 377, 2016)
Ilaria Marigo et al.
CANCER CELL (2016)
IRF8 Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional and Plasmacytoid Dendritic Cells, Respectively
Dorine Sichien et al.
IMMUNITY (2016)
Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species
Martin Guilliams et al.
IMMUNITY (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Maxim V. Kuleshov et al.
NUCLEIC ACIDS RESEARCH (2016)
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick et al.
CANCER IMMUNOLOGY RESEARCH (2016)
GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c+MHCII+ Macrophages and Dendritic Cells
Julie Helft et al.
IMMUNITY (2015)
Batf3 maintains autoactivation of Irf8 for commitment of a CD8α+ conventional DC clonogenic progenitor
Gary E. Grajales-Reyes et al.
NATURE IMMUNOLOGY (2015)
Identification of cDC1-and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow
Andreas Schlitzer et al.
NATURE IMMUNOLOGY (2015)
Overcoming Antigen Escape with CAR T-cell Therapy
Hollie J. Jackson et al.
CANCER DISCOVERY (2015)
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru et al.
ONCOIMMUNOLOGY (2015)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow
Christian Thomas Mayer et al.
BLOOD (2014)
Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells
Brian Ruffell et al.
CANCER CELL (2014)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Edward Y. Chen et al.
BMC BIOINFORMATICS (2013)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach
Connie P. M. Duong et al.
PLOS ONE (2013)
Paths to stemness: building the ultimate antitumour T cell
Luca Gattinoni et al.
NATURE REVIEWS CANCER (2012)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Markus Chmielewski et al.
CANCER RESEARCH (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity
Leanne X. J. Wang et al.
CANCER RESEARCH (2010)
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism
Dimitra Zotos et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo
Shalin H. Naik et al.
NATURE IMMUNOLOGY (2007)
Human ErbB-2 (Her-2) transgenic mice: A model system for testing Her-2 based vaccines
MP Piechocki et al.
JOURNAL OF IMMUNOLOGY (2003)
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors
NM Haynes et al.
BLOOD (2002)
Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma
NM Haynes et al.
JOURNAL OF IMMUNOLOGY (2001)
Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL
PK Darcy et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
